Lacosamida Hikma (Lacosamide)

• Lacosamide is used to manage focal seizure disorders within the epilepsy disease family.
• Partial‑onset seizures: Reduces seizure frequency as adjunctive therapy in epilepsy patients.
• Focal epilepsy: Provides seizure control when added to existing antiepileptic regimens.
• Adjunctive therapy in refractory epilepsy: Enhances overall seizure management in patients not controlled by other medications.

• Lacosamide selectively enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing the inactive state of these channels, it diminishes repetitive neuronal firing and reduces hyper‑excitability that underlies seizure generation. The drug’s action is independent of the fast inactivation process, offering a distinct mechanism among antiepileptic agents and contributing to its efficacy in focal seizure control.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild to moderate stomach upset.
• Fatigue: increased tiredness or lack of energy.
• Headache: mild to moderate cranial pain.
• Diplopia: transient double vision.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation.
• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Respiratory depression: marked reduction in breathing effort.
• Hepatic injury: elevated liver enzymes or hepatitis.

When prescribing lacosamide, clinicians should observe several precautionary measures to ensure patient safety.

• Cardiac monitoring: assess ECG for PR‑interval changes before and during therapy.
• Renal impairment: adjust dose in patients with reduced kidney function.
• Hepatic disease: use with caution in individuals with liver dysfunction.
• Concomitant CNS depressants: monitor for additive sedation or respiratory effects.
• Discontinuation: avoid abrupt cessation to prevent seizure worsening.
• Store at room temperature: keep in original container, protect from moisture and light.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels.
• Strong CYP3A4 inducers (e.g., carbamazepine): may reduce lacosamide effectiveness.
• Other sodium‑channel blockers (e.g., phenytoin): risk of additive cardiac conduction effects.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: possible reduction in hormonal efficacy.
• Alcohol: enhanced central nervous system depression.
• Valproate: may alter lacosamide clearance requiring dose review.